天地恒一制药股份有限公司

About 天地恒一制药股份有限公司

Founded in 2006, Tiandi Hengyi Pharmaceutical Co., Ltd. (formerly Hunan Tiandi Hengyi Pharmaceutical Co., Ltd.) is a market-oriented, R&D-driven comprehensive modern pharmaceutical enterprise located in the National Liuyang Economic and Technological Development Zone (also known as Changsha National Biological Industry Base). The company has over 700 employees, with management and technical backbones primarily born in the 1980s, and over 75% of the total workforce holding a bachelor's degree or higher. The company is mainly engaged in the research and development, production, and sales of clinically therapeutic prescription drugs, and is one of the pharmaceutical companies in Hunan Province with strong R&D capabilities, wide marketing network coverage, and rapid development. In 2019, the company was included in the "China Pharmaceutical Industry Top 100 Series," ranking 86th in the "China Traditional Chinese Medicine Enterprise TOP100." The company's products include traditional Chinese medicine (TCM) preparations, chemical drugs, and raw materials. As of the end of 2019, it had obtained 18 drug production approvals, 9 new drug certificates, and 7 raw material drug production approvals (and registration numbers). The company has accumulated over 60 drug R&D projects in progress or declared to the National Medical Products Administration, including generic and innovative drugs for both TCM and chemical drugs. The company's marketing center has established a TCM business unit, a chemical drug business unit, and a third-tier market business unit, with more than 20 provincial offices nationwide, creating a "one body, two wings" all-terminal market layout. After more than a decade of market cultivation, it has built a sales network covering the whole country. With a professional and meticulous marketing model and excellent business and academic teams, it has established an excellent domestic prescription drug brand in the national pharmaceutical market. The company's main TCM product, Zhuifeng Tougu Capsule, is a national Class A medical insurance drug, which has entered the national TOP10 list of TCM clinical drugs for the musculoskeletal system. It is used clinically in over 2,000 secondary and above medical institutions and more than 5,000 primary healthcare institutions nationwide, relieving or improving the pain of millions of patients annually. Other key products have certain market competitiveness in the fields of rheumatic and orthopedic drugs, immunomodulatory drugs, and TCM antibacterial and antiviral drugs. Several products have entered the TOP20 list in their respective market segments, and four key products have achieved annual sales revenue of over 100 million yuan per product, forming a multi-level product echelon. After ten years of R&D accumulation, chemical generic drugs that have passed or are deemed to have passed the consistency evaluation of chemical generic drugs are gradually being launched, giving them a significant advantage in national centralized procurement, enabling rapid market share acquisition, and expanding brand influence and enterprise scale. The generic drug strategy of "excellent quality, lower prices" and the international cooperation strategy of "going out, bringing in" are gradually being implemented in the market. The company's improved new drug and global innovative drug research projects have made progress, which will provide sustainable development momentum for the company. The company has consistently invested in drug R&D since its inception, with an annual R&D investment of about 10%. Currently, R&D personnel account for nearly one-third of the total number of employees, including 10 PhD holders and over 100 Master's degree holders. The company has established a 5,000-square-meter R&D laboratory and a pilot-scale and commercial production platform of over 30,000 square meters. As of the end of 2019, the company had undertaken 8 national and provincial scientific research projects. It has obtained 12 invention patents and 3 design patents, and nearly 80 trademarks, with "Tiandi Hengyi" being a famous trademark of Hunan Province. The company is a nationally recognized High-tech Enterprise, National Intellectual Property Advantage Enterprise, Hunan Provincial Enterprise Technology Center, and a jointly established unit of the Hunan Provincial Engineering Research Center for Osteoarticular Diseases Drugs and the Hunan Provincial Engineering Research Center for Drug Quality Evaluation. The company has co-built a new drug screening and evaluation platform with Hunan University and Hunan University of Chinese Medicine, and has established scientific research cooperation with several universities inside and outside Hunan Province. In 2017, it established a postdoctoral research station and established joint training programs for full-time master's students and commissioned training programs for part-time master's students with institutions such as Hunan University of Chinese Medicine and Wuhan University. The company's production center has more than ten production lines, including tablets, capsules, small injections, large infusions, sterile powders, lyophilized powders, granules, pills, chemical raw materials, and TCM extracts. It is one of the first pharmaceutical enterprises in Hunan Province to pass the new version of GMP and has established a raw material and formulation production management system that meets international drug standards, as well as an EHS management system. To improve the industrial chain layout and enhance the modernization and quality assurance of TCM, the company has acquired 2,000 mu of forest land to build the "Tiandi Hengyi Modern TCM Industrial Park," establishing a research, demonstration planting, and traditional Chinese medicine decoction piece processing base for major TCM varieties. The "fully automated digital TCM extraction workshop," with an investment of 120 million yuan, was officially put into operation in February 2020, realizing automated production processes and digital traceability of product quality. It is a demonstration workshop for intelligent manufacturing of TCM in Hunan Province. To meet the domestic and international simultaneous declaration needs of the company's in-progress products and the production capacity requirements of current commercialized products, the company has newly built chemical formulation workshops and high-end raw material production bases that comply with ICH requirements, providing drugs that comply with the regulations of ICH protocol countries, enabling the co-production of the company's chemical drug formulation products for domestic and international markets. Tiandi Hengyi's corporate goal is to "create a business with meaning and value," dedicated to improving human health and promoting scientific progress. We uphold the business philosophy of "patient-centered cooperation and win-win," gathering a group of young people with entrepreneurial spirit and scientific dreams. We believe in the core values of "Integrity, Dedication, Struggle, Persistence, Sharing, Innovation" and strive for our ideals!